Barely Significant
← all excerpts

Safety and feasibility of anlotinib in children with high risk, recurrent or refractory sarcomas: an open-label, single-centre, single-arm, phase Ia/Ib trial.

EClinicalMedicine · 2025 · PMC12151220 · PMID 40496885

Europe PMCDOI
1
hedged sentence
0.0400
closest p · 0.8× alpha
0.0400
boldest claim

The sentences

showed a trendP = 0.04actually significant
The incidence of abdominal pain showed a trend of increase with higher steady-state trough concentration (C min,ss ) [OR 1.08 (95% CI: 1.01–1.17), P = 0.04] and steady-state AUC τ [OR 1.00 (95% CI: 1.00–1.01), P = 0.04].

also in 33,237 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.